Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06213831 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
A Phase 1 study of Prurigo Nodularis, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 20
- Study locations
NCT06213831: Completed Phase 1 study of Prurigo Nodularis, sponsored by Incyte Corporation.
NCT06213831 is a Phase 1 study of Prurigo Nodularis that has completed, run by Incyte Corporation. The registered enrollment target is 23 participants, below the 228-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06213831, a Phase 1 study of Prurigo Nodularis, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).
Primary Outcome
Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.
Conditions Studied
Interventions
- DRUG Ruxolitinib Cream 1.5%
Study Locations (20)
California
- First Oc Dermatology - Fountain Valley
- Amicis Research Center Valencia - Northridge
- Clinical Science Institute Clinical Research Specialists Inc - Santa Monica
Florida
- Advanced Pharma Cr, Llc - Miami
- Sullivan Dermatology North Miami Beach Office - North Miami Beach
- Olympian Clinical Research - Tampa
Arizona
- Saguaro Dermatology - Phoenix
- Affiliated Dermatology - Scottsdale
Michigan
- Oakland Hills Dermatology Pc - Auburn Hills
- Revival Research Institute, Llc Troy - Troy
Texas
- Dermresearch, Inc. - Austin
- North Texas Center For Clinical Research Ntccr - Frisco
Idaho
- St Lukes Clinic Dermatology Ketchum - Ketchum
Indiana
- Dawes Fretzin Clinical Research Group Llc - Indianapolis
Kentucky
- Equity Medical - Bowling Green
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2024-02-27 |
| Est. Completion | 2025-07-17 |
| Phase | Phase 1 |
What the finished NCT06213831 record still lists
NCT06213831 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 228-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib Cream 1.5% is the first listed.
NCT06213831 names 20 study sites across 13 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06213831 about?
NCT06213831 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream". This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).
What is the current status of trial NCT06213831?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2024-02-27. Estimated completion is 2025-07-17.
What conditions does trial NCT06213831 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT06213831?
The interventions under investigation include: Ruxolitinib Cream 1.5% (DRUG).
Who is sponsoring clinical trial NCT06213831?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06213831 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Idaho, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06213831's enrollment target sits among peer trials
23 13th of 14 higher than 2 of 14 other Prurigo Nodularis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prurigo Nodularis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
Upadacitinib for Prurigo Nodularis
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
RECRUITING · Phase 3
-
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
RECRUITING
-
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI